# Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil

> **NCT02946125** · PHASE2 · COMPLETED · sponsor: **Eyenovia Inc.** · enrollment: 12 (actual)

## Conditions studied

- Mydriasis

## Interventions

- **COMBINATION_PRODUCT:** MDD-administered EYN-1601
- **DRUG:** Phenylephrine 2.5% Eyedrop
- **DRUG:** Phenylephrine 10% Eyedrop

## Key facts

- **NCT ID:** NCT02946125
- **Lead sponsor:** Eyenovia Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02946125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02946125, "Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02946125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*